Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased Longeveron Inc. (NASDAQ: LGVN) Class A common stock pursuant to or traceable to the Company's February 12, 2021 initial public offering ("IPO"), or between February 12, 2021 and August 12, 2021. The complaint seeks remedies pursuant to the Securities Act of 1933 and Securities Exchange Act of 1934. Longeveron is a clinical stage biotechnology company that engages in developing cellular therapies for aging-related and life-threatening conditions. The Company's lead investigational product is Lomecel-B, which is currently in Phase 2b of its trial ("Phase 2b Aging Frailty Trial").

If you suffered a loss due to Longeveron Inc.'s misconduct, click here.

Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B

According to the complaint, Longeveron conducted its IPO on February 12, 2021, issuing 2.66 million Class A shares at $10.00 per share, for approximate proceeds of $24.7 million. However, defendants negligently prepared the Offering Documents in connection with the IPO. Specifically, defendants failed to disclose that: (i) Lomecel-B was not as effective in treating aging frailty as defendants had led investors to believe; (ii) accordingly, Lomecel-B's clinical and commercial prospects with respect to aging frailty were overstated; and (iii) as a result, the Offering Documents and defendants' public statements during the class period were materially false and misleading.

On August 13, 2021, Longeveron issued two press releases – one announcing topline results of the Phase 2b Againg Frailty Trial and one addressing the Company's financial results for the second quarter of 2021. Both press releases disclosed that Lomecel-B had "not achiev[ed] … statistical significance for the pairwise comparison to placebo" with respect to the primary efficacy endpoint. On this news, Longeveron's stock price fell almost 28%, to close at $3.90 per share on August 13, 2021, representing a 61% total decline from the IPO price.

If you purchased shares of Longeveron (LGVN) pursuant to the Company's February 12, 2021 IPO, or between February 12 and August 12, 2021, you have until November 12, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas

(800) 350-6003

adumas@robbinsllp.com

Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Longeveron Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.